Aurobindo Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AUROBINDO PHARMA
AUROBINDO PHARMA has five hundred and fifty-three approved drugs.
There are twenty-five tentative approvals on AUROBINDO PHARMA drugs.
Summary for Aurobindo Pharma
| US Patents: | 0 |
| Tradenames: | 417 |
| Ingredients: | 389 |
| NDAs: | 553 |
| Patent Litigation for Aurobindo Pharma: | See patent lawsuits for Aurobindo Pharma |
| PTAB Cases with Aurobindo Pharma as petitioner: | See PTAB cases with Aurobindo Pharma as petitioner |
Drugs and US Patents for Aurobindo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | TRAMADOL HYDROCHLORIDE | tramadol hydrochloride | TABLET;ORAL | 203494-001 | Mar 31, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Ltd | FOSINOPRIL SODIUM | fosinopril sodium | TABLET;ORAL | 091163-001 | Mar 30, 2011 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | PREGABALIN | pregabalin | CAPSULE;ORAL | 205321-004 | Mar 29, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | SAFINAMIDE MESYLATE | safinamide mesylate | TABLET;ORAL | 215902-002 | Jun 14, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Aurobindo Pharma | STAVUDINE | stavudine | FOR SOLUTION;ORAL | 077774-001 | Dec 29, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Aurobindo Pharma Ltd | CEFPODOXIME PROXETIL | cefpodoxime proxetil | FOR SUSPENSION;ORAL | 065409-002 | Jun 8, 2007 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Aurobindo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,105,783 | ⤷ Start Trial |
| Aurobindo Pharma Usa | MAXZIDE-25 | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-003 | May 13, 1988 | 4,444,769 | ⤷ Start Trial |
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,444,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
